Information Provided By:
Fly News Breaks for November 12, 2019
ALXN
Nov 12, 2019 | 07:11 EDT
SunTrust analyst Robyn Karnauskas initiated coverage of Alexion with a Buy rating and $125 price target. The analyst says she sees upside for the stock in 2020 as patent uncertainty dissipates, noting that while her model assumes aggressive impact from biosimilars, competition,and price erosion, she believes that the stock reflects "even worse declines".
News For ALXN From the Last 2 Days
ALXN
Dec 11, 2019 | 15:47 EST
Biotech Analyst Nierengarten hosts Gil Wolfe, Irvin and Rosemary Smith, Professor & Chairman of the Neurology Department at Jacobs School of Medicine/Biomedical Sciences, to discuss new therapies in Myasthenia Gravis in a healthcare expert Breakfast Meeting being held in New York on December 16 hosted by Wedbush.